Recurrent VulvoVaginal Candidiasis (RVVC) is a debilitating , chronic infectious condition that affects millions of women. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain.
Although the physical symptoms can be distressing, often the emotional and psychological consequences of the recurrent infections affect sufferers most. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine, yet despite the high prevalence, there are currently no agents in the United States approved to treat the condition.
What is the Trial About
Recurrent vulvovaginal candidiasis (RVVC) is a persistent vaginal infection, occurring at least 3 times a year. Vaginal yeast infections are usually treated with an antifungal medicine. However, side effects of those medicines may limit their long-term use.
The investigational medication is thought to have less impact on other processes in the body than currently available antifungal medicines and is, therefore, hoped to have fewer and/or less troublesome side effects.
Want To Be Part of This Study
You may be able to take part in this trial if you:
- currently have a vaginal yeast infection (that you are not currently treating)
- have had at least 2 other vaginal yeast infections in the past 12 months
If you do not have a yeast infection now, you may still be able to participate in the trial the next time you experience a yeast infection. Please contact us to learn more about your options. By contacting us, you are under no obligation to participate in the trial – participation is completely voluntary.
This trial is available for women and girls age 12 years of age and older who are generally healthy and not pregnant. If you are less than 18 years of age, your parents or guardians will be asked for their permission as well.
If you join the study:
- All Trial Related Care and Trial Medications will be Provided at No Cost.
- Qualified Participants will be Compensated for Time and Travel.
VT-1161 has the potential to be a safe and effective agent for the treatment of patients with invasive, mucosal, or superficial fungal infections.